SOLEUS CAPITAL MASTER FUND, L.P. 13D and 13G filings for Jasper Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-11 4:00 pm Purchase | 2024-12-31 | 13G | Jasper Therapeutics, Inc. JSPR | SOLEUS CAPITAL MASTER FUND, L.P. | 1,494,420 9.960% | 507,324 (+51.40%) | Filing |
| 2024-02-02 09:50 am Purchase | 2023-12-31 | 13G | Jasper Therapeutics, Inc. JSPR | SOLEUS CAPITAL MASTER FUND, L.P. | 987,096 8.800% | 987,096 (New Position) | Filing |